Healthcare Industry News: Novacea
News Release - December 4, 2006
Bayhill Therapeutics Names Paul Westberg Vice President of Business DevelopmentPALO ALTO, Calif.--(HSMN NewsFeed)--Bayhill Therapeutics Inc., a clinical-stage biotechnology company developing innovative therapies for autoimmune diseases, has named Paul Westberg to the newly created position of Vice President of Business Development. Mr. Westberg will be responsible for developing strategic partnerships for some of Bayhill's key therapeutic programs.
Mr. Westberg comes to Bayhill from Novacea Inc., where he was Vice President of Business Development. At Novacea, Mr. Westberg created and led the company's business and corporate development efforts surrounding its in-licensing business model. He closed two significant product licensing deals in three years, expanding and diversifying Novacea's oncology pipeline. Mr. Westberg was instrumental in raising substantial private equity funding for Novacea and in successfully completing its initial public offering.
Prior to joining Novacea, Mr. Westberg directed business development efforts at Deltagen Inc. and Collabra Pharma. He also served in finance roles at Genentech Inc. and Aviron Inc. At Genentech, Mr. Westberg led a corporate-wide working group responsible for producing a long range plan used to more effectively manage Genentech's development pipeline, commercial products, and corporate initiatives. He also provided financial and analytical support for in-licensing and co-development opportunities at the firm.
Mr. Westberg earned a Master's degree in Business Administration from the University of California, Berkeley, and a Bachelor of Arts degree in Applied Mathematics from the University of California, San Diego.
"We are pleased to have Paul join our senior management team at a time when Bayhill is rapidly advancing multiple programs through the clinic," said Dr. Mark Schwartz, Chief Executive Officer. "Paul's track record of successfully completing significant deals will prove instrumental as Bayhill's partnering efforts gather momentum and become a critical company focus."
"I am excited to be joining Bayhill at such an important period of the company's growth and development," said Mr. Westberg. "Bayhill has a strong management team, excellent science and a rapidly developing pipeline that may change the way the autoimmune diseases are treated, and I am pleased to be a part of such a promising firm."
About Bayhill Therapeutics
Bayhill Therapeutics Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapeutics that fundamentally alter the way autoimmune diseases are treated. The company has developed two therapeutic platforms with broad applicability to a range of autoimmune diseases. Bayhill's BHT-DNA autoimmune vaccine is designed to eliminate disease-causing cells without effecting normal protective immune system cells. BHT-DNA is being studied in a Phase II trial for multiple sclerosis and a Phase I/II trial for autoimmune diabetes. Bayhill's second therapeutic is an oligonucleotide in preclinical development for systemic lupus erythematosus.
More information about Bayhill Therapeutics is available at www.bayhilltherapeutics.com.
Source: Bayhill Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.